| Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase … JP Sharman, M Egyed, W Jurczak, A Skarbnik, JM Pagel, IW Flinn, ... The Lancet 395 (10232), 1278-1291, 2020 | 639 | 2020 |
| Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis AR Mato, C Nabhan, MC Thompson, N Lamanna, DM Brander, B Hill, ... Haematologica 103 (5), 874, 2018 | 426 | 2018 |
| The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL IW Flinn, P Hillmen, M Montillo, Z Nagy, Á Illés, G Etienne, J Delgado, ... Blood, The Journal of the American Society of Hematology 132 (23), 2446-2455, 2018 | 359 | 2018 |
| The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients SP Treon, JJ Castillo, AP Skarbnik, JD Soumerai, IM Ghobrial, ... Blood, The Journal of the American Society of Hematology 135 (21), 1912-1915, 2020 | 310 | 2020 |
| Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients AR Mato, BT Hill, N Lamanna, PM Barr, CS Ujjani, DM Brander, C Howlett, ... Annals of Oncology 28 (5), 1050-1056, 2017 | 265 | 2017 |
| Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience AR Mato, C Nabhan, PM Barr, CS Ujjani, BT Hill, N Lamanna, ... Blood, The Journal of the American Society of Hematology 128 (18), 2199-2205, 2016 | 216 | 2016 |
| Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States AR Mato, M Thompson, JN Allan, DM Brander, JM Pagel, CS Ujjani, ... Haematologica 103 (9), 1511, 2018 | 168 | 2018 |
| Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve … JP Sharman, M Egyed, W Jurczak, A Skarbnik, JM Pagel, IW Flinn, ... Leukemia 36 (4), 1171-1175, 2022 | 160 | 2022 |
| Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial IO Rosas, G Diaz, RL Gottlieb, SM Lobo, P Robinson, BD Hunter, ... Intensive care medicine 47, 1258-1270, 2021 | 119 | 2021 |
| Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy AR Mato, LE Roeker, R Jacobs, BT Hill, N Lamanna, D Brander, ... Clinical Cancer Research 26 (14), 3589-3596, 2020 | 115 | 2020 |
| ELEVATE TN: phase 3 study of acalabrutinib combined with obinutuzumab (O) or alone vs O plus chlorambucil (Clb) in patients (Pts) with treatment-naive chronic lymphocytic … JP Sharman, V Banerji, LM Fogliatto, Y Herishanu, T Munir, R Walewska, ... Blood 134, 31, 2019 | 104 | 2019 |
| Tumor lysis, adverse events, and dose adjustments in 297 venetoclax-treated CLL patients in routine clinical practice LE Roeker, CP Fox, TA Eyre, DM Brander, JN Allan, SJ Schuster, ... Clinical Cancer Research 25 (14), 4264-4270, 2019 | 78 | 2019 |
| Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents LE Roeker, P Dreger, JR Brown, OB Lahoud, TA Eyre, DM Brander, ... Blood advances 4 (16), 3977-3989, 2020 | 75 | 2020 |
| Outcomes of front‐line ibrutinib treated CLL patients excluded from landmark clinical trial AR Mato, LE Roeker, JN Allan, JM Pagel, DM Brander, BT Hill, ... American journal of hematology 93 (11), 1394-1401, 2018 | 67 | 2018 |
| Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced‐dose ibrutinib: results from a multi‐centre study. AR Mato, C Timlin, C Ujjani, A Skarbnik, C Howlett, R Banerjee, ... British journal of haematology 181 (2), 2018 | 67 | 2018 |
| COVID-19 in patients with CLL: improved survival outcomes and update on management strategies LE Roeker, TA Eyre, MC Thompson, N Lamanna, AR Coltoff, MS Davids, ... Blood, The Journal of the American Society of Hematology 138 (18), 1768-1773, 2021 | 59 | 2021 |
| Comparative outcomes after haploidentical or unrelated donor bone marrow or blood stem cell transplantation in adult patients with hematological malignancies M Baker, H Wang, SD Rowley, L Cai, AL Pecora, A Skarbnik, DH Vesole, ... Biology of blood and marrow transplantation 22 (11), 2047-2055, 2016 | 57 | 2016 |
| Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy AR Mato, N Ghosh, SJ Schuster, N Lamanna, JM Pagel, IW Flinn, ... Blood, The Journal of the American Society of Hematology 137 (20), 2817-2826, 2021 | 47 | 2021 |
| Mantle cell lymphoma: state of the art AP Skarbnik, AH Goy Clin Adv Hematol Oncol 13 (1), 44-55, 2015 | 44 | 2015 |
| The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies AP Skarbnik, S Faderl Therapeutic advances in hematology 8 (3), 99-105, 2017 | 32 | 2017 |
